Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott R Plotkin

Showing results (161-170 of 201) with videos related to

Pageof 21
Sort By:
American Journal of Medical Genetics. Part A|February 13, 2013
Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteriaScott R Plotkin, Jaishri O Blakeley, D Gareth Evans, et al.
Journal of Neuro-Oncology|May 28, 2025
Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104Vihang Nakhate, Ina Ly, Alona Muzikansky, et al.
Nature Communications|February 11, 2026
NKG2D upregulation sensitizes tumors to combined anti-PD1 and anti-VEGF therapy and prevents hearing lossSimeng Lu, Zhenzhen Yin, Limeng Wu, et al.
Biorxiv : the Preprint Server for Biology|February 17, 2023
Co-Targeting IL-6 and EGFR signaling for the treatment of schwannomatosis and associated painZhenzhen Yin, Limeng Wu, Yanling Zhang, et al.
Neuro-Oncology|July 9, 2018
EPH receptor signaling as a novel therapeutic target in NF2-deficient meningiomaSteven P Angus, Janet L Oblinger, Timothy J Stuhlmiller, et al.
Genome Medicine|April 11, 2025
A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locationsL Nicolas Gonzalez Castro, Avishai Gavish, Lillian Bussema, et al.
The British Journal of Dermatology|October 25, 2023
A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trialsLaura Fertitta, Christina Bergqvist, Kavita Y Sarin, et al.
Neurology|November 20, 2013
Recommendations for imaging tumor response in neurofibromatosis clinical trialsEva Dombi, Simone L Ardern-Holmes, Dusica Babovic-Vuksanovic, et al.
NPJ Precision Oncology|December 5, 2017
Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survivalOvidiu C Andronesi, Morteza Esmaeili, Ronald J H Borra, et al.
Neuro-Oncology|July 6, 2013
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastomaChristine Lu-Emerson, Matija Snuderl, Nathaniel D Kirkpatrick, et al.
Pageof 21

Showing results (161-170 of 201) with videos related to

Sort By:
Pageof 21
American Journal of Medical Genetics. Part A|February 13, 2013
Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteriaScott R Plotkin, Jaishri O Blakeley, D Gareth Evans, et al.
Journal of Neuro-Oncology|May 28, 2025
Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104Vihang Nakhate, Ina Ly, Alona Muzikansky, et al.
Nature Communications|February 11, 2026
NKG2D upregulation sensitizes tumors to combined anti-PD1 and anti-VEGF therapy and prevents hearing lossSimeng Lu, Zhenzhen Yin, Limeng Wu, et al.
Biorxiv : the Preprint Server for Biology|February 17, 2023
Co-Targeting IL-6 and EGFR signaling for the treatment of schwannomatosis and associated painZhenzhen Yin, Limeng Wu, Yanling Zhang, et al.
Neuro-Oncology|July 9, 2018
EPH receptor signaling as a novel therapeutic target in NF2-deficient meningiomaSteven P Angus, Janet L Oblinger, Timothy J Stuhlmiller, et al.
Genome Medicine|April 11, 2025
A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locationsL Nicolas Gonzalez Castro, Avishai Gavish, Lillian Bussema, et al.
The British Journal of Dermatology|October 25, 2023
A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trialsLaura Fertitta, Christina Bergqvist, Kavita Y Sarin, et al.
Neurology|November 20, 2013
Recommendations for imaging tumor response in neurofibromatosis clinical trialsEva Dombi, Simone L Ardern-Holmes, Dusica Babovic-Vuksanovic, et al.
NPJ Precision Oncology|December 5, 2017
Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survivalOvidiu C Andronesi, Morteza Esmaeili, Ronald J H Borra, et al.
Neuro-Oncology|July 6, 2013
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastomaChristine Lu-Emerson, Matija Snuderl, Nathaniel D Kirkpatrick, et al.
Pageof 21